| Literature DB >> 28737945 |
Se Jong Oh1,2, Min Hwan Kim1, Sang Jin Han1, Kyung Jun Kang1, In Ok Ko1, YoungSoo Kim3, Ji-Ae Park1, Jae Yong Choi1, Kyo Chul Lee1, Dae Yoon Chi4, Yong Jin Lee1, Kyeong Min Kim2,5.
Abstract
To evaluate the efficacy of 18F-FC119S as a positron emission tomography (PET) radiopharmaceutical for the imaging of Alzheimer's disease (AD), we studied the drug absorption characteristics and distribution of 18F-FC119S in normal mice. In addition, we evaluated the specificity of 18F-FC119S for β-amyloid (Aβ) in the AD group of an APP/PS1 mouse model and compared it with that in the wild-type (WT) group. The behavior of 18F-FC119S in the normal mice was characteristic of rapid brain uptake and washout patterns. In most organs, including the brain, 18F-FC119S reached its maximum concentration within 1 min and was excreted via the intestine. Brain PET imaging of 18F-FC119S showed highly specific binding of the molecule to Aβ in the cortex and hippocampus. The brain uptake and binding values for the AD group were higher than those for the WT group. These results indicated that 18F-FC119S would be a candidate PET imaging agent for targeting Aβ plaque.Entities:
Keywords: 18F-FC119S; Alzheimer’s disease; β-amyloid
Mesh：
Substances：
Year: 2017 PMID： 28737945 DOI： 10.1021/acs.molpharmaceut.7b00351
Source DB: PubMed Journal: Mol Pharm ISSN： 1543-8384 Impact factor: 4.939